194 related articles for article (PubMed ID: 29275295)
41. Overexpression of EZH2 is associated with the poor prognosis in osteosarcoma and function analysis indicates a therapeutic potential.
Sun R; Shen J; Gao Y; Zhou Y; Yu Z; Hornicek F; Kan Q; Duan Z
Oncotarget; 2016 Jun; 7(25):38333-38346. PubMed ID: 27223261
[TBL] [Abstract][Full Text] [Related]
42. Aberrant expression of enhancer of zeste homologue 2, correlated with HIF-1α, refines relapse risk and predicts poor outcome for breast cancer.
Dong M; Fan XJ; Chen ZH; Wang TT; Li X; Chen J; Lin Q; Wen JY; Ma XK; Wei L; Ruan DY; Lin ZX; Liu Q; Wu XY; Wan XB
Oncol Rep; 2014 Sep; 32(3):1101-7. PubMed ID: 25017254
[TBL] [Abstract][Full Text] [Related]
43. High expression of Polycomb group protein EZH2 predicts poor survival in salivary gland adenoid cystic carcinoma.
Vékony H; Raaphorst FM; Otte AP; van Lohuizen M; Leemans CR; van der Waal I; Bloemena E
J Clin Pathol; 2008 Jun; 61(6):744-9. PubMed ID: 18326020
[TBL] [Abstract][Full Text] [Related]
44. Diagnostic and prognostic role of HBME-1, galectin-3, and β-catenin in poorly differentiated and anaplastic thyroid carcinomas.
Rossi ED; Straccia P; Palumbo M; Stigliano E; Revelli L; Lombardi CP; Santeusanio G; Pontecorvi A; Fadda G
Appl Immunohistochem Mol Morphol; 2013 May; 21(3):237-41. PubMed ID: 23235344
[TBL] [Abstract][Full Text] [Related]
45. Anaplastic and poorly differentiated thyroid carcinoma: therapeutic strategies and treatment outcome of 52 consecutive patients.
Siironen P; Hagström J; Mäenpää HO; Louhimo J; Heikkilä A; Heiskanen I; Arola J; Haglund C
Oncology; 2010; 79(5-6):400-8. PubMed ID: 21455012
[TBL] [Abstract][Full Text] [Related]
46. Aberrant lipid metabolism in anaplastic thyroid carcinoma reveals stearoyl CoA desaturase 1 as a novel therapeutic target.
von Roemeling CA; Marlow LA; Pinkerton AB; Crist A; Miller J; Tun HW; Smallridge RC; Copland JA
J Clin Endocrinol Metab; 2015 May; 100(5):E697-709. PubMed ID: 25675381
[TBL] [Abstract][Full Text] [Related]
47. Expression of the enhancer of zeste homolog 2 in biopsy specimen predicts chemoresistance and survival in advanced non-small cell lung cancer receiving first-line platinum-based chemotherapy.
Xu C; Hao K; Hu H; Sheng Z; Yan J; Wang Q; Yu L
Lung Cancer; 2014 Nov; 86(2):268-73. PubMed ID: 25262426
[TBL] [Abstract][Full Text] [Related]
48. Poorly differentiated carcinoma of thyroid: Case report of an uncommon entity.
Khetrapal S; Rana S; Jetley S; Jairajpuri Z
J Cancer Res Ther; 2018; 14(5):1142-1144. PubMed ID: 30197365
[TBL] [Abstract][Full Text] [Related]
49. EZH2 overexpression in different immunophenotypes of breast carcinoma and association with clinicopathologic features.
Guo S; Li X; Rohr J; Wang Y; Ma S; Chen P; Wang Z
Diagn Pathol; 2016 Apr; 11():41. PubMed ID: 27113214
[TBL] [Abstract][Full Text] [Related]
50. County Median Family Income Is an Independent Prognostic Factor for Stage IV Anaplastic Thyroid Cancer.
Li MU; Gu S; Mao R; Ning Y; Trivedi N; Siddiqui A; Li P; Huo L
Anticancer Res; 2019 Feb; 39(2):949-956. PubMed ID: 30711980
[TBL] [Abstract][Full Text] [Related]
51. High expression of CD10 in anaplastic thyroid carcinomas.
Nakazawa T; Kondo T; Vuong HG; Odate T; Kawai M; Tahara I; Kasai K; Inoue T; Oishi N; Mochizuki K; Ito K; Katoh R
Histopathology; 2018 Sep; 73(3):492-499. PubMed ID: 29791034
[TBL] [Abstract][Full Text] [Related]
52. Aberrant differential expression of EZH2 and H3K27me3 in extranodal NK/T-cell lymphoma, nasal type, is associated with disease progression and prognosis.
Liu J; Liang L; Huang S; Nong L; Li D; Zhang B; Li T
Hum Pathol; 2019 Jan; 83():166-176. PubMed ID: 30218753
[TBL] [Abstract][Full Text] [Related]
53. Thioredoxin interacting protein (TXNIP) is a novel tumor suppressor in thyroid cancer.
Morrison JA; Pike LA; Sams SB; Sharma V; Zhou Q; Severson JJ; Tan AC; Wood WM; Haugen BR
Mol Cancer; 2014 Mar; 13():62. PubMed ID: 24645981
[TBL] [Abstract][Full Text] [Related]
54. Epigenetic modifications in poorly differentiated and anaplastic thyroid cancer.
Sasanakietkul T; Murtha TD; Javid M; Korah R; Carling T
Mol Cell Endocrinol; 2018 Jul; 469():23-37. PubMed ID: 28552796
[TBL] [Abstract][Full Text] [Related]
55. Expression of EZH2 in renal cell carcinoma as a novel prognostic marker.
Lee HW; Choe M
Pathol Int; 2012 Nov; 62(11):735-41. PubMed ID: 23121604
[TBL] [Abstract][Full Text] [Related]
56. Increased expression of EZH2 in Merkel cell carcinoma is associated with disease progression and poorer prognosis.
Harms KL; Chubb H; Zhao L; Fullen DR; Bichakjian CK; Johnson TM; Carskadon S; Palanisamy N; Harms PW
Hum Pathol; 2017 Sep; 67():78-84. PubMed ID: 28739498
[TBL] [Abstract][Full Text] [Related]
57. Co-expression of Bmi1 and EZH2 as an independent poor prognostic factor in esophageal squamous cell carcinoma.
Ha SY; Kim SH
Pathol Res Pract; 2012 Aug; 208(8):462-9. PubMed ID: 22766604
[TBL] [Abstract][Full Text] [Related]
58. Clinical and prognostic relevance of EZH2 in breast cancer: A meta-analysis.
Wang X; Hu B; Shen H; Zhou H; Xue X; Chen Y; Chen S; Han Y; Yuan B; Zhao H; Zhi Q; Kuang Y
Biomed Pharmacother; 2015 Oct; 75():218-25. PubMed ID: 26271144
[TBL] [Abstract][Full Text] [Related]
59. Enhancer of zeste homolog 2 (EZH2) expression in bladder cancer.
Warrick JI; Raman JD; Kaag M; Bruggeman T; Cates J; Clark P; DeGraff DJ
Urol Oncol; 2016 Jun; 34(6):258.e1-6. PubMed ID: 26976725
[TBL] [Abstract][Full Text] [Related]
60. Prevalence of Enhancer of Zeste Homolog 2 in Patients with Resected Small Cell Lung Cancer.
Toyokawa G; Takada K; Tagawa T; Kinoshita F; Kozuma Y; Matsubara T; Haratake N; Takamori S; Akamine T; Hirai F; Yamada Y; Hamamoto R; Oda Y; Maehara Y
Anticancer Res; 2018 Jun; 38(6):3707-3711. PubMed ID: 29848731
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
